Provectus Biopharmaceuticals, Inc. PVCT
0.05 USD 0.00 (-4.17%)
At closeNov 11, 2026, 4:00 PM EST
0.0415 Day range 0.0473
0.038 52-week range 0.077
- YTD
- -17.86%
- 1 year
- -23.33%
News
globenewswire.com VisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company Showcase KNOXVILLE, Tenn., July 22, 2026 (GLOBE NEWSWIRE) -- VisiRose, Inc. (“VisiRose” or the “Company”), the clinical-stage ophthalmology subsidiary of Provectus Biopharmaceuticals, Inc. (“Provectus”)…
globenewswire.com Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose Peer-reviewed preclinical melanoma research finds Provectus's synthetic small molecule can both stimulate anti-tumor immunity and suppress peripheral immune cells at the same dose. A recently…
globenewswire.com Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections New IP covers topical rose bengal sodium ophthalmic composition against MRSA and other resistant Gram-positive bacteria without requiring light activation. VisiRose to hold exclusive ophthalmic…
globenewswire.com Provectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium) Under Veripure, Provectus is supplying qualified medical researchers with the same pharmaceutical grade rose bengal sodium API used in clinical trials. Veripure is also a quality benchmark,…
seekingalpha.com Provectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call Transcript Provectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call Transcript
globenewswire.com Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders KNOXVILLE, Tenn., June 08, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that its 2026 annual stockholder meeting (the…
globenewswire.com Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal. KNOXVILLE,…
globenewswire.com Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis New BPEI preclinical data address treatment protocol, corneal biochemical environment, fungal resistance mechanism, MRSA biofilm inhibition, and enhanced cysticidal activity KNOXVILLE, Tenn. , May…
globenewswire.com Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee Company Marks First Annual Meeting at Historic Perkins Place Office Building as It Prepares to Relocate Its Headquarters from First Horizon Plaza Tower KNOXVILLE, Tenn. , April 20, 2026 (GLOBE…
globenewswire.com Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment KNOXVILLE, Tenn., April 02, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly published independent preclinical research…
defenseworld.net Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Up 16,004.0% in December Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling…
globenewswire.com Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy KNOXVILLE, Tenn., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of independent preclinical research…
globenewswire.com Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer KNOXVILLE, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a preclinical study of its lead…
globenewswire.com Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer KNOXVILLE, Tenn., June 26, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of preclinical research by…
globenewswire.com Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders KNOXVILLE, Tenn., June 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2025 annual stockholder meeting (the…
globenewswire.com Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose,…
seekingalpha.com Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript Provectus Biopharmaceuticals, Inc. (OTC:PVCT) Q4 2024 Results Conference Call November 14, 2024 2:00 PM ET Company Participants Alyssa Barry - Co-Founder & Principal of Investor Relations, Alliance…
benzinga.com Stocks That Hit 52-Week Highs On Tuesday